<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137993</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_OLZ_401</org_study_id>
    <nct_id>NCT02137993</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia</brief_title>
  <official_title>A Multi-center, Randomized, Double Blind, Parallel, PhaseⅣ Trial to Evaluate the Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of A-prexa compared to
      Zyprexa in patients with schizophrenia, schizophreniform disorder and schizoaffective
      disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline at 6 week in total PANSS score</measure>
    <time_frame>6 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at 1, 2, 4 and 6 week in total PANSS score.</measure>
    <time_frame>6 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder to be decreased of 30% or more in PANSS total score from baseline at 6 week</measure>
    <time_frame>6 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at 6 week in total CGI-S score</measure>
    <time_frame>6 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate in CGI-I score of 'very much improved', 'much improved' and 'minimally improved'</measure>
    <time_frame>6 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizophreniform Disorder</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>A-prexa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-prexa 5, 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zyprexa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zyprexa 5, 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-prexa</intervention_name>
    <description>A-prexa 5-20 mg for 6 weeks</description>
    <arm_group_label>Zyprexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zyprexa</intervention_name>
    <description>Zyprexa 5-20 mg for 6 weeks</description>
    <arm_group_label>A-prexa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 years to 65 years

          -  Schizophrenia patient with an acute exacerbation

          -  Understand the requirement of the study and voluntarily consent to participate in the
             study

        Exclusion Criteria:

          -  Patients who have another psychiatric disorders

          -  Patients who have unstable medical conditions

          -  Patients who have clinically important abnormalities of liver function test (＞2.5 fold
             of upper normal limit), ECG and vital sign at screening visit

          -  Uncontrolled diabetic patients (plasma glucose level is more than 126 mg/dl in fasting
             condition)

          -  Patients who have a history of an allergic reaction to olanzapine

          -  Patient who have no clinical response to take two or more different atypical
             anti-psychotics for more than 4 weeks.

          -  Patient who take clozapine within 12 weeks before screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2014</study_first_submitted>
  <study_first_submitted_qc>May 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <last_update_submitted>May 11, 2014</last_update_submitted>
  <last_update_submitted_qc>May 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

